A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection

NCT00006154 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

165

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Indinavir sulfate
DRUG: Ritonavir
DRUG: Abacavir sulfate
DRUG: Efavirenz
DRUG: Stavudine
DRUG: Didanosine
DRUG: Aldesleukin

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)